Executive summary

This study reported that among 79 pediatric/young adult patients evaluated, 47.9% (23/48) of XRT patients and 48.4% (15/31) of PBT patients had acute grade 2/3 toxicity. For the late RIST, 17.5% (7/40 with known toxicity profile) of XRT patients and 29.0% (9/31) of PBT patients had grade 1/2 toxicity. This difference of -11.5% in grade 1/2 toxicity between XRT and PBT was not statistically significant (P = 0.25). 

Key content topics
Top cancer treatments